Scientific Programme
The 22nd Annual ENETS Conference
5 - 7 March 2025
Download the final programme
22nd Annual ENETS Conference
Wednesday, 05 March 2025
REGISTRATION & COFFEE
Time: Wednesday 08:00 - 08:45
Room: Foyer
22nd Annual ENETS Conference | Welcome and opening
Time: Wednesday 08:45 - 08:55
Room: Auditorium Hall (S1)
Moderators:
Rocio Garcia-Carbonero, ESP
15th ENETS Postgraduate Course | Welcome and opening
Time: Wednesday 08:55 - 09:00
Room: Auditorium Hall (S1)
Moderators:
Eric Baudin, FRA / Mairéad Geraldine McNamara, GBR
Basic science | Welcome and opening
Time: Wednesday 08:55 - 09:00
Room: Theatre Hall (S2)
Moderators:
Mauro Cives, ITA / Jérôme Cros, FRA / Ilaria Marinoni, SUI
15th ENETS Postgraduate Course | Session A: Standardisation of baseline evaluation in patients with advanced NET
Time: Wednesday 09:00 - 10:30
Room: Auditorium Hall (S1)
Moderators:
Martyn Caplin, GBR / Eva Tiensuu Janson, SWE
| 09:00 - 09:15 | Grade
|
| Atsuko Kasajima, GER |
| 09:15 - 09:30 | Tumour burden: What is relevant?
|
| Angela Lamarca, ESP |
| 09:30 - 09:45 | Looking for SSTR/FDG expression: What do I learn in addition to the grade and CSI results
|
| Marina Tsoli, GRE |
| 09:45 - 10:00 | The importance of identifying the primary at the metastatic stage
|
| Beata Kos-Kudła, POL |
| 10:00 - 10:30 | Panel discussion
|
Basic science | Keynote speech
Time: Wednesday 09:00 - 09:30
Room: Theatre Hall (S2)
Moderators:
Jérôme Cros, FRA / Talya Dayton, ESP
| 09:00 - 09:25 | Angiogenesis and metabolic adaptation
|
| Oriol Casanovas, ESP |
| 09:25 - 09:30 | Discussion
|
Basic science | Session 1: How do we bring the microenvironment into our preclinical models?
Time: Wednesday 09:30 - 10:40
Room: Theatre Hall (S2)
Moderators:
Jérôme Cros, FRA / Talya Dayton, ESP
| 09:30 - 09:45 | Established models in NET: Limits and opportunities
|
| Ilaria Marinoni, SUI |
| 09:45 - 10:00 | 3D bioprinting reconstruction of tumour microenvironment in vitro
|
| Cristina Scielzo, ITA |
| 10:00 - 10:15 | Use of precision cut slice to explore NET
|
| Fiona Oakley, GBR |
| 10:15 - 10:20 | Discussion
|
| 10:20 - 10:27 | Oral abstract presentation: Developing innovative, genetically modified, proliferation-regulated patient-derived models representing human well-differentiated GEP-NETs for drug screening
|
| James Yao, USA |
| 10:27 - 10:30 | Discussion
|
| 10:30 - 10:37 | Oral abstract presentation: Single-nucleus profiling of the tumour microenvironment in SI-NET patients
|
| Netta Mäkinen, USA |
| 10:37 - 10:40 | Discussion
|
COFFEE BREAK
Time: Wednesday 10:30 - 11:00
Room: Foyer
15th ENETS Postgraduate Course | Session B: State of the art approach to localised NET
Time: Wednesday 11:00 - 12:30
Room: Auditorium Hall (S1)
Moderators:
Massimo Falconi, ITA / Raj Srirajaskanthan, GBR
| 11:00 - 11:15 | Endoscopic assessment of lesions: What the interventional endoscopist needs to know |
| 11:00 - 11:15 | Digestive NET
|
| Dermot O'Toole, IRL |
| 11:15 - 11:45 | Surgical resection of localised NET: Indications, limitations and type of surgery |
| 11:15 - 11:30 | Digestive / GEP-NET
|
| Peter Stalberg, SWE |
| 11:30 - 11:45 | Lung NET
|
| Luca Bertolaccini, ITA |
| 11:45 - 12:00 | Lymph node resection: Update on recent N status classification
|
| Nehara Begum, GER |
| 12:00 - 12:30 | Panel discussion
|
Basic science | Session 2: Genome stability, immunity and ARID1A in neuroendocrine tumours – Is it important?
Time: Wednesday 11:00 - 12:30
Room: Theatre Hall (S2)
Moderators:
Mauro Cives, ITA / Anguraj Sadanandam, GBR
| 11:00 - 11:15 | Role of genomic instability in PanNET progression
|
| Ilaria Marinoni, SUI |
| 11:15 - 11:30 | ARID1A and genomic stability
|
| Fulvio Chiacchiera, ITA |
| 11:30 - 11:45 | ARID1A and anti-tumour immunity
|
| Jérôme Cros, FRA |
| 11:45 - 12:00 | Discussion
|
| 12:00 - 12:07 | Oral abstract presentation: A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours
|
| Eleonora Pelle, USA |
| 12:07 - 12:10 | Discussion
|
| 12:10 - 12:17 | Oral abstract presentation: Elucidating the role of high mobility group box 3 (Hmgb3) during progression and response to radiation therapy in pancreatic neuroendocrine tumours
|
| Nilakshi Kulathunga, CAN |
| 12:17 - 12:20 | Discussion
|
| 12:20 - 12:27 | Oral abstract presentation: Genetic trajectory and clonal evolution of non-functional pancreatic neuroendocrine tumours with lymph node and liver metastasis
|
| Junli Wu, CHN |
| 12:27 - 12:30 | Discussion
|
LUNCH
Time: Wednesday 12:30 - 13:15
Room: Foyer
Clinical Science | Mini oral presentations
Time: Wednesday 13:15 - 14:00
Room: Auditorium Hall (S1)
Moderators:
Sebastian Maasberg, GER / Alia Munir, GBR
| 13:15 - 13:19 | Multivariate survival analyses of 544 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC) given first-line chemotherapy (NORDIC NEC 2)
|
| Halfdan Sorbye, NOR |
| 13:19 - 13:21 | Discussion
|
| 13:21 - 13:25 | Clinical and gut microbiota (GM) markers of aggressive carcinoid syndrome
|
| Rachel Riechelmann, BRA |
| 13:25 - 13:27 | Discussion
|
| 13:28 - 13:32 | Efficacy and safety of surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Updated results from a single-arm, phase II study
|
| Wei Wang, CHN |
| 13:32 - 13:35 | Discussion
|
| 13:35 - 13:39 | Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Safety and exploratory efficacy results from a phase 2, randomised, parallel-group study
|
| Łukasz Hajac, POL |
| 13:39 - 13:41 | Discussion
|
| 13:42 - 13:46 | Characterisation and prognostic impact of carcinoid syndrome in bronchial neuroendocrine tumours
|
| Ségolène Hescot, FRA |
| 13:46 - 13:48 | Discussion
|
| 13:48 - 13:52 | Clinical presentation and outcomes of sporadic neuroendocrine neoplasms in young adults: International multicentre analysis
|
| Anna Malczewska-Herman, POL |
| 13:52 - 13:54 | Discussion
|
| 13:54 - 13:58 | Clinical characterisation of patients with familial midgut neuroendocrine tumours (FM-NETs) based on a comparison with the large population-based GTE/RENATEN cohort
|
| Thomas Hunaut, FRA |
| 13:58 - 14:00 | Discussion
|
Basic Science | Mini oral presentations
Time: Wednesday 13:15 - 14:00
Room: Theatre Hall (S2)
Moderators:
Talya Dayton, ESP / Anguraj Sadanandam, GBR
| 13:15 - 13:19 | RNA splicing as a key regulatory player with translational potential in pulmonary neuroendocrine neoplasms (lungNETs)
|
| Laura Gutiérrez Camacho, ESP |
| 13:19 - 13:22 | Discussion
|
| 13:23 - 13:27 | Familial inactivating glucagon receptor mutation resulting in pancreatic neuroendocrine tumours with metastatic potential, somatic MEN1 mutations, and a heterozygous phenotype
|
| Jelka Kuiper, NED |
| 13:27 - 13:30 | Discussion
|
| 13:31 - 13:35 | Optimising the establishment of patient-derived models for neuroendocrine neoplasms
|
| Maria Hernandez Llorens, ESP |
| 13:35 - 13:38 | Discussion
|
| 13:39 - 13:43 | Analysis of the mutational landscape of pancreatic neuroendocrine tumours before and after temozolomide treatment
|
| Elena Trevisani, ITA |
| 13:43 - 13:46 | Discussion
|
| 13:46 - 13:50 | A novel nonpeptide drug conjugate (NDC) for the treatment of somatostatin receptor 2-expressing tumours
|
| David Metz, USA |
| 13:50 - 13:53 | Discussion
|
| 13:53 - 13:57 | Defective DNA repair promotes progression of small intestinal neuroendocrine tumors despite a lack of common genomic drivers
|
| Felix Bolduan, GER |
| 13:57 - 14:00 | Discussion
|
15th ENETS Postgraduate Course | Session C: Controversies in NEN
Time: Wednesday 14:00 - 15:30
Room: Auditorium Hall (S1)
Moderators:
Eric Baudin, FRA / Wouter W. de Herder, NED
| 14:00 - 14:05 | Opening remarks
|
| Eric Baudin, FRA |
| 14:05 - 14:45 | Part 1: Time for routine MGMT screening in advanced NET |
| 14:05 - 14:15 | Pros
|
| Thomas Walter, FRA |
| 14:15 - 14:25 | Cons
|
| Halfdan Sorbye, NOR |
| 14:25 - 14:45 | Audience vote and discussion
|
| Eric Baudin, FRA / Wouter W. de Herder, NED / Halfdan Sorbye, NOR / Thomas Walter, FRA |
| 14:45 - 15:25 | Part 2: PRRT front-line in advanced SRI positive in high grade 2 or grade 3 GEP-NET |
| 14:45 - 14:55 | Pros
|
| Hans Hofland, NED |
| 14:55 - 15:05 | Cons
|
| Mairéad Geraldine McNamara, GBR |
| 15:05 - 15:25 | Audience vote and discussion
|
| Eric Baudin, FRA / Wouter W. de Herder, NED / Hans Hofland, NED / Mairéad Geraldine McNamara, GBR |
| 15:25 - 15:30 | Concluding remarks
|
| Wouter W. de Herder, NED |
| 14:00 - 14:15 | Serotonin-associated fibrosis
|
| Leo Hofland, NED |
| 14:15 - 14:30 | Molecular mechanisms of mesenteric fibrosis in small bowel NET
|
| Krista Rombouts, GBR |
| 14:30 - 14:45 | Targeting small bowel NET through serotonin metabolism
|
| Po Hien Ear, USA |
| 14:45 - 15:00 | Discussion
|
| 15:00 - 15:07 | Oral abstract presentation: Epigenetic exploration of mesenteric fibrosis indicates epigenetic disruption of DAXX is driving metastatic potential in small intestinal neuroendocrine tumours
|
| Amy Webster, GBR |
| 15:07 - 15:10 | Discussion
|
| 15:10 - 15:17 | Oral abstract presentation: The usefulness of circulating fibrosis markers in detection of carcinoid heart disease
|
| Tobias Stemann Lau, DEN |
| 15:17 - 15:20 | Discussion
|
| 15:20 - 15:27 | Oral abstract presentation: Establishing a standardised histopathological grading system for mesenteric fibrosis in small intestinal neuroendocrine tumours
|
| Eva van der Slik, NED |
| 15:27 - 15:30 | Discussion
|
COFFEE BREAK
Time: Wednesday 15:30 - 16:00
Room: Foyer
15th ENETS Postgraduate Course | Session D: MDT – Severe carcinoid syndrome control
Time: Wednesday 16:00 - 17:30
Room: Auditorium Hall (S1)
Moderators:
Eric Baudin, FRA / Christos Toumpanakis, GBR
| 16:00 - 16:05 | Case presentation
|
| Simona Glasberg, ISR |
| 16:05 - 16:20 | Option 1: My decision is to increase SSA dosage
|
| Anja Rinke, GER |
| 16:20 - 16:35 | Option 2: My decision is to use locoregional therapy, including surgery
|
| Matthieu Faron, FRA |
| 16:35 - 16:50 | Option 3: My decision is to use non-SSA systemic options
|
| Francesca Spada, ITA |
| 16:50 - 16:55 | Audience vote
|
| 16:55 - 17:30 | MDT panel discussion
|
| Clarisse Dromain, SUI / Matthieu Faron, FRA / Simona Glasberg, ISR / Wendy Martin, GBR / Anja Rinke, GER / Anna Sowa-Staszczak, POL / Francesca Spada, ITA / Staffan Welin, SWE |
Basic science | Session 4: Tumour liquid biopsies
Time: Wednesday 16:00 - 17:30
Room: Theatre Hall (S2)
Moderators:
Justo P. Castaño, ESP / Ernst-Jan Speel, NED
| 16:00 - 16:15 | cfDNA, methylated cfDN and circulating tumour cell
|
| Timon Vandamme, BEL |
| 16:15 - 16:30 | Circulating microvesicules and miRNA
|
| Peter Igaz, HUN |
| 16:30 - 16:45 | Circulating proteomics in NET
|
| Samir M. Hanash, USA |
| 16:45 - 17:10 | Discussion
|
| 17:10 - 17:17 | Oral abstract presentation: A methylation-based classifier for neuroendocrine tumour detection using smMIP technology
|
| Joe Ibrahim, BEL |
| 17:17 - 17:20 | Discussion
|
| 17:20 - 17:27 | Oral abstract presentation: Exploring the interplay between RNA methylation and splicing dysregulation in neuroendocrine tumours
|
| Daniel Ruiz-Palacios, ESP |
| 17:27 - 17:30 | Discussion
|
15th ENETS Postgraduate Course | Closing comments
Time: Wednesday 17:30 - 17:40
Room: Auditorium Hall (S1)
Moderators:
Eric Baudin, FRA
Basic science | Closing comments
Time: Wednesday 17:30 - 17:40
Room: Theatre Hall (S2)
Moderators:
Mauro Cives, ITA
ENETS Projects
Time: Wednesday 17:40 - 18:00
Room: Auditorium Hall (S1)
Moderators:
Rocio Garcia-Carbonero, ESP
WELCOME RECEPTION
Time: Wednesday 18:00 - 18:30
Room: Foyer
Thursday, 06 March 2025
Satellite Symposium I – Industry sponsored
Time: Thursday 07:45 - 08:45
Room: Theatre Hall (S2)
Clinical science | Session 1: Theranostics in NENs – Integrating experience for a brighter future
Time: Thursday 08:45 - 10:15
Room: Auditorium Hall (S1)
Moderators:
Nicola Fazio, ITA / Simona Glasberg, ISR
| 08:45 - 09:00 | Lutetium-labelled SSA: "One size does not fit all" approach in NENs
|
| Valentina Ambrosini, ITA |
| 09:00 - 09:05 | Discussion
|
| 09:05 - 09:20 | Alpha- versus beta-radionuclide therapies: Do we have the knowledge for their use in the clinical routine?
|
| Richard P. Baum, GER |
| 09:20 - 09:25 | Discussion
|
| 09:25 - 09:40 | Optimising PRRT sequencing in NETs
|
| Ulrich Knigge, DEN |
| 09:40 - 09:45 | Discussion
|
| 09:45 - 09:55 | SPARC Europe
|
| Nicola Fazio, ITA |
| 09:55 - 10:02 | Oral abstract presentation: 2. endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive PaNET – The OCLURANDOM trial
|
| Eric Baudin, FRA |
| 10:02 - 10:05 | Discussion
|
| 10:05 - 10:12 | Oral abstract presentation: Efficacy and safety of [177Lu]Lu-edotreotide vs. everolimus in patients with grade 1 or grade 2 gastroenteropancreatic neuroendocrine tumours: COMPETE phase 3 trial
|
| Jaume Capdevila, ESP |
| 10:12 - 10:15 | Discussion
|
COFFEE BREAK
Time: Thursday 10:15 - 10:45
Room: Foyer
Satellite Symposium II – Industry sponsored
Time: Thursday 10:15 - 10:45
Room: Theatre Hall (S2)
Clinical science | Session 2A: Lessons from targets – Personalised therapies from bench to bedside
Time: Thursday 10:45 - 12:15
Room: Auditorium Hall (S1)
Moderators:
Mauro Cives, ITA / Margot Tesselaar, NED
| 10:45 - 11:00 | Biological grounds for personalised medicine failure in NENs
|
| Chrissie Thirlwell, GBR |
| 11:00 - 11:05 | Discussion
|
| 11:05 - 11:20 | Personalised medicine in NENs: Some successful targets
|
| Melissa Frizziero, GBR |
| 11:20 - 11:25 | Discussion
|
| 11:25 - 11:40 | How to implement biomarkers into clinical practice
|
| Aurel Perren, SUI |
| 11:40 - 11:45 | Discussion
|
| 11:45 - 11:52 | Oral abstract presentation: Improved assessment of gene rearrangements by targeting non-coding DNA regions in patients diagnosed with pancreatic neuroendocrine neoplasms
|
| Chiara Agnoletto, ITA |
| 11:52 - 11:55 | Discussion
|
| 11:55 - 12:02 | Oral abstract presentation: Novel genomic score predicts survival with immune checkpoint blockade in neuroendocrine neoplasms
|
| Tanvi Brar, USA |
| 12:02 - 12:05 | Discussion
|
| 12:05 - 12:12 | Oral abstract presentation: Efficacy of immune checkpoint inhibitors (ICI) in patients with advanced pancreatic NETs displaying high TMB and MMR alterations following treatment with alkylating agents
|
| Louis de Mestier, FRA |
| 12:12 - 12:15 | Discussion
|
Clinical science | Session 2B: Abstract session
Time: Thursday 10:45 - 12:15
Room: Theatre Hall (S2)
Moderators:
Adina Croitoru, ROU / John Ramage, GBR
| 10:45 - 10:52 | Radiolabelled somatostatin receptor (SSTR) antagonist versus agonist for peptide receptor radionuclide therapy (PRRT) in patients with SSTR positive neuroendocrine tumours – A retrospective basket study
|
| Christopher Eigler, SUI |
| 10:52 - 10:55 | Discussion
|
| 10:55 - 11:02 | Emergence of DNA damage repair clonal hematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumours
|
| Julien Hadoux, FRA |
| 11:02 - 11:05 | Discussion
|
| 11:05 - 11:12 | Treatment response and survival in 163 metastatic colorectal neuroendocrine carcinomas: A prospective cohort from the nordic NEC registry
|
| Siren Morken, NOR |
| 11:12 - 11:15 | Discussion
|
| 11:15 - 11:22 | Survival of 10,418 lung neuroendocrine tumours after surgical resection: Who needs follow-up and for how long?
|
| Marie Line El Asmar, GBR |
| 11:22 - 11:25 | Discussion
|
| 11:25 - 11:32 | [68Ga]Ga-DOTA-Exendin-4 PET/CT for the localisation of insulinoma: Results of an international, dual-centre, retrospective, open-label real-world imaging study
|
| Julia Fricke, SUI |
| 11:32 - 11:35 | Discussion
|
| 11:35 - 11:42 | Targeted beta- plus auger and conversion electron therapy with terbium-161 labelled somatostatin receptor antagonist DOTA-LM3 – BETA plus phase 0 study
|
| Julia Fricke, SUI |
| 11:42 - 11:45 | Discussion
|
| 11:45 - 11:52 | Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial
|
| Panpan Zhang, CHN |
| 11:52 - 11:55 | Discussion
|
| 11:55 - 12:02 | Intraoperative beta-probe for pathological tissue detection in GEP-NET patients: A prospective phase II trial
|
| Emilio Bertani, ITA |
| 12:02 - 12:05 | Discussion
|
| 12:05 - 12:12 | The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)
|
| Susumu Hijioka, JPN |
| 12:12 - 12:15 | Discussion
|
LUNCH
Time: Thursday 12:15 - 14:15
Room: Foyer
Satellite Symposium III – Industry sponsored
Time: Thursday 12:45 - 14:15
Room: Theatre Hall (S2)
Clinical science | Session 3A: Unlocking the power of AI – How will it transform the management of NENs?
Time: Thursday 14:15 - 15:25
Room: Auditorium Hall (S1)
Moderators:
Clarisse Dromain, SUI / Raj Srirajaskanthan, GBR
| 14:15 - 14:30 | Advanced applications of AI in image analysis for NETs
|
| Mario Jreige, SUI |
| 14:30 - 14:45 | AI to integrate pathology and omics
|
| Matthieu Foll, FRA |
| 14:45 - 15:00 | AI for drug design
|
| Bilal Mateen, GBR |
| 15:00 - 15:15 | Roundtable discussion
|
| 15:15 - 15:22 | Oral abstract presentation: Automated (Artificial Intelligence) vs. manual evaluation of the Somatostatin-receptor 2A and proliferation marker Ki-67 in neuroendocrine neoplasms – A pilot study
|
| Daniel Kaemmerer, GER |
| 15:22 - 15:25 | Discussion
|
Translational science | Session 3B: Abstract session
Time: Thursday 14:15 - 15:25
Room: Theatre Hall (S2)
Moderators:
Aurel Perren, SUI / Ernst-Jan Speel, NED
| 14:15 - 14:22 | Spatial and temporal intratumour heterogeneity of pancreatic neuroendocrine tumours (PanNET)
|
| Zaima Afzal Awan, FRA |
| 14:22 - 14:25 | Discussion
|
| 14:25 - 14:32 | Molecular analysis of non-functioning PanNETs of the alpha lineage reveals new subtypes and mechanisms of progression
|
| Simona Avanthay, SUI |
| 14:32 - 14:35 | Discussion
|
| 14:35 - 14:42 | Uncovering cell-state heterogeneity in large-cell panNEC indicates potentially targetable aberrant brain type neuronal de-differentiation
|
| Olivia Debnath, USA |
| 14:42 - 14:45 | Discussion
|
| 14:45 - 14:52 | Multicentric ENETS morphological and molecular appraisal of high-grade gastroenteropancreatic neuroendocrine neoplasms (HG-GEP-NEN): Distinguishing NET G3 from NEC
|
| Matthieu Tihy, FRA |
| 14:52 - 14:55 | Discussion
|
| 14:55 - 15:02 | BH3-mimetic drugs elicit cell death of neuroendocrine tumours in preclinical models – An emerging therapeutic strategy for NETs
|
| Iacovos Michael, CAN |
| 15:02 - 15:05 | Discussion
|
| 15:05 - 15:12 | NET-IMPRESS: A novel methylation-based assay to diagnose and monitor NET patients using liquid biopsies
|
| Laura Mariën, BEL |
| 15:12 - 15:15 | Discussion
|
| 15:15 - 15:22 | Development of new 3D in vitro models for pancreatic neuroendocrine tumours (PanNETs)
|
| Anna Battistella, ITA |
| 15:22 - 15:25 | Discussion
|
Life Achievement Award
Time: Thursday 15:25 - 15:45
Room: Auditorium Hall (S1)
Moderators:
Rocio Garcia-Carbonero, ESP
| 15:25 - 15:35 | Laudatio
|
| Anne Couvelard, FRA |
| 15:35 - 15:45 | Recipient and keynote address
|
| Philippe Ruszniewski, FRA |
COFFEE BREAK
Time: Thursday 15:45 - 16:15
Room: Foyer
Clinical science | Session 4A: Challenges in the treatment of localised & locally advanced NETs
Time: Thursday 16:15 - 17:45
Room: Auditorium Hall (S1)
Moderators:
Detlef Bartsch, GER / Anna Koumarianou, GRE
| 16:15 - 16:30 | Progredient small bowel ischemia caused by SI-NEN
|
| Sophie Deguelte, FRA |
| 16:30 - 16:35 | Discussion
|
| 16:35 - 16:50 | Locally advanced pNET – Is there a role for neoadjuvant treatment?
|
| Stefano Partelli, ITA |
| 16:50 - 16:55 | Discussion
|
| 16:55 - 17:10 | Is there a role of surgery for locally advanced GEP-NET G3 and NEC?
|
| Andrea Frilling, GBR |
| 17:10 - 17:15 | Discussion
|
| 17:15 - 17:30 | Tumour bleeding of advanced bronchial NET – Treatment options
|
| Anne-Marie Dingemans, NED |
| 17:30 - 17:35 | Discussion
|
| 17:35 - 17:40 | Oral abstract presentation: Long-term prognosis of parenchyma-sparing vs. oncologic resections for distal pancreatic non-functional neuroendocrine tumours ≤ 3cm: A real-world data study (CSPAC-NEN-5)
|
| Zheng Li, CHN |
| 17:40 - 17:45 | Oral abstract presentation: Survival and optimal follow-up cut off of lung neuroendocrine tumours after surgery – Experience of a high-volume centre over 25 years
|
| Mohamed Mortagy, GBR |
Clinical science | Session 4B: ENETS – INCA joint session
Time: Thursday 16:15 - 17:45
Room: Theatre Hall (S2)
Moderators:
Stephanie Alband, USA / Rocio Garcia-Carbonero, ESP
| 16:15 - 16:18 | Opening
|
| Stephanie Alband, USA / Rocio Garcia-Carbonero, ESP |
| 16:18 - 16:31 | Meaningful involvement of patients in NEN research
|
| Thorvardur Halfdanarson, USA |
| 16:31 - 16:45 | Patients partnering in research internationally and locally
|
| Meredith Cummins, AUS |
| 16:45 - 16:58 | Aligning researcher and patient priorities – What the future holds
|
| Timon Vandamme, BEL |
| 16:58 - 17:05 | Designing research with patient input – FORCE NEN project
|
| Faye Tukker-Wijntjes, NED |
| 17:05 - 17:18 | How can we improve NEN research globally
|
| Simron Singh, CAN |
| 17:18 - 17:42 | Discussion
|
| 17:42 - 17:45 | Wrap-up and closing comments
|
| Stephanie Alband, USA / Rocio Garcia-Carbonero, ESP |
ENETS General Assembly 2025 (Entry for ENETS members only)
Time: Thursday 18:00 - 19:30
Room: Theatre Hall (S2)
Friday, 07 March 2025
Clinical science | Session 5A: ENETS – NANETS joint session: Future perspectives and opportunities for global development in NENs
Time: Friday 09:00 - 10:30
Room: Auditorium Hall (S1)
Moderators:
Jennifer Chan, USA / Rocio Garcia-Carbonero, ESP
| 09:00 - 09:15 | Recent advances and promising approaches in treatment of NET
|
| Thorvardur Halfdanarson, USA |
| 09:15 - 09:20 | Discussion
|
| 09:20 - 09:35 | Recent advances and promising approaches in treatment of NEC
|
| Jaume Capdevila, ESP |
| 09:35 - 09:40 | Discussion
|
| 09:40 - 09:50 | Considerations in developing clinical guidelines: Is global convergence feasible? – Part 1
|
| Marianne Pavel, GER |
| 09:50 - 10:00 | Considerations in developing clinical guidelines: Is global convergence feasible? – Part 2
|
| Jennifer Chan, USA |
| 10:00 - 10:05 | Discussion
|
| 10:05 - 10:15 | Clinical trial development and coordinated efforts to facilitate progress and success – Part 1
|
| Julien Hadoux, FRA |
| 10:15 - 10:25 | Clinical trial development and coordinated efforts to facilitate progress and success – Part 2
|
| Simron Singh, CAN |
| 10:25 - 10:30 | Discussion
|
Clinical science | Session 5B: Nurse & Dietitian symposium
Time: Friday 09:00 - 10:30
Room: Theatre Hall (S2)
Moderators:
Yasmin Chotai de Lima, GBR / Wendy Martin, GBR
| 09:00 - 09:05 | Welcome and update
|
| Wendy Martin, GBR |
| 09:05 - 09:10 | Update from dietitians' perspective
|
| Yasmin Chotai de Lima, GBR |
| 09:10 - 09:50 | Part 1 – Challenging issues living with NEN |
| Moderators: Mette Borre, Lise Munk Plum |
| 09:10 - 09:17 | Oral abstract presentation: FIT-NETs: Assessing the effects of an exercise programme on the physical and emotional well-being of patients with advanced G1-2 NETs of GEP or unknown origin
|
| Beatriz Anton Pascual, ESP |
| 09:17 - 09:20 | Discussion
|
| 09:20 - 09:27 | Oral abstract presentation: Follow-up analysis of group nutritional education in patients with neuroendocrine neoplasms (GEDNEN Course): A novel approach with proven acceptability
|
| Alia Munir, GBR |
| 09:27 - 09:30 | Discussion
|
| 09:30 - 09:50 | Intimacy and sexuality in neuroendocrine cancer diagnosis
|
| Irene Wotherspoon, GBR |
| 09:50 - 10:25 | Part 2 – Interactive session: The role of the NET nurse specialist around Europe |
| Moderators: Wendy Martin |
| 09:50 - 10:00 | Introduction and launch of the ENETS nurses and dietitians questionnaire
|
| Wanda Geilvoet, NED |
| 10:00 - 10:05 | NET nurse specialist in Italy
|
| Alessia Lorusso, ITA |
| 10:05 - 10:10 | NET nurse specialist in Denmark
|
| Lise Munk Plum, DEN |
| 10:10 - 10:15 | NET nurse specialist in the Netherlands
|
| Wendy Wolters, NED |
| 10:15 - 10:25 | Discussion
|
| Wanda Geilvoet, NED |
| 10:25 - 10:30 | Closing comments
|
| Yasmin Chotai de Lima, GBR / Wendy Martin, GBR |
COFFEE BREAK
Time: Friday 10:30 - 11:00
Room: Foyer
Clinical science | Session 6: Best NET publications – What’s new in the field?
Time: Friday 11:00 - 12:00
Room: Auditorium Hall (S1)
Moderators:
Rocio Garcia-Carbonero, ESP / Nicholas Reed, GBR
| 11:00 - 11:25 | Basic science
|
| Justo P. Castaño, ESP |
| 11:25 - 12:00 | Clinical and translational science
|
| Gregory Kaltsas, GRE |
Awards Ceremony
Time: Friday 12:00 - 12:35
Room: Auditorium Hall (S1)
Moderators:
Rocio Garcia-Carbonero, ESP / Nicholas Reed, GBR
Closing comments
Time: Friday 12:35 - 12:40
Room: Auditorium Hall (S1)
Moderators:
Rocio Garcia-Carbonero, ESP
LUNCH
Time: Friday 12:40 - 13:30
Room: Foyer